| Name | Title | Contact Details |
|---|
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.
HealthLynked (OTCQB: HLYK) provides a solution for both patient members and providers to improve healthcare by efficiently exchanging medical information. The HealthLynked Network is a cloud-based platform that allows members to connect with their healthcare providers and take control of their medical data. Members can enter their medications, allergies, past surgeries, and personal health records into one convenient online and secure location. Participating healthcare providers can connect with their current and future patients through the HealthLynked Network. Providers also get the benefit of using HealthLynked marketing tools to communicate with their active and inactive patients to improve patient retention, access accurate patient information, and provide efficient online scheduling.
Sigma Telemed is a York, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Eye Health Northwest is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
electroCore is, a US based electroceutical healthcare company, which is developing a range of non-invasive Vagus Nerve Stimulation (nVNS) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. Initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electroCore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the US (head office), Germany (German and European head office), UK, Italy, Australia, and Canada.